「匈牙利口腔顎面醫師學會正式推薦維麥康AVEMAR為口腔癌患者的醫療營養輔助品」
維麥康AVEMAR經匈牙利政府正式核准以「癌症病患使用之醫療營養品」登記販售，成為匈牙利最多癌症病人使用的醫療輔助品，且外銷至歐洲、美國、亞洲多國。維麥康AVEMAR是唯一經過Phase III人體臨床實驗證實的癌症醫療營養輔助品；其製造與核准程序與抗癌藥物規格相同。在2006年，匈牙利口腔顎面醫師學會在匈牙利醫學期刊正式發表一份人體臨床實驗報告意見書，內容正式推薦頭，頸及口腔惡性腫瘤的病患使用維麥康AVEMAR，並強調使用維麥康AVEMAR的確能發揮以下功效：
- 顯著減輕病情的惡化
- 顯著增加五年的存活率
- 改善病患的生活品質
- 減少氧化壓力(Oxidative Stress)對病患健康之影響
使用維麥康AVEMAR能幫助癌症患者降低癌症復發轉移的機率，也能減緩化療的副作用，支持病患完成整個療程，詳細內容請看產品功效。
早期口腔癌3年的存活率可達80%，5年的存活率也可有60%，但若是晚期(第三、四期)則存活率降至50%以下。口腔癌的復發大部分發生在3年內，患者治療後的第一年，每月建議追蹤檢查一次，第二年每2-3個月追蹤檢查一次，第3年每3-4個月追蹤檢查一次，第四、五年以後可每半年追蹤檢查一次。而在治療過後，持續追蹤的過程中，維麥康AVEMAR是重要的輔助品，能積極有效的幫助口腔癌患者降低癌症復發轉移的機會，而不是讓患者被動的等待癌症再度捲土重來的一天。
在這篇報告書中的實驗顯示，45名患有第二期、第三期口腔鱗狀細胞癌的患者參與AVEMAR的臨床研究。其中23名接受癌症標準治療（SAT，包含放射線手術及術後放射線治療或輔助性化學治療），另外22名患者除了接受癌症標準治療外還配合服用一年的維麥康AVEMAR。結果顯示，患者接受了標準治療 +維麥康AVEMAR後，復發率僅為4.3%，而接受標準治療的患者為54.5%；
標準治療+維麥康AVEMAR的新轉移率降為4.3%，標準治療的患者為22.7%；
標準治療+維麥康AVEMAR的疾病惡化率為8.7%，標準治療的患者為59.1%。
這樣的人體臨床試驗結果，讓我們必須將維麥康AVEMAR介紹給被口腔癌嚴重威脅的病患們，有效的實驗結果與完整的使用安全，讓治療後或治療中的患者們，能多做一些努力來捍衛自己的健康，有臨床實驗證實的維麥康AVEMAR一起幫助您長期對抗口腔癌。
Regional lymph node metastases occur relatively more frequently in oral cavity squamous cell carcinomas than in other types of head and neck cancer. Their presence indicates an aggressive and therapy-resistant form of the disease. Responsiveness to chemotherapy is poor. Current therapeutic strategies include radical surgery, postoperative radiation (percutaneous teletherapy and/or afterloading brachytherapy), or adjuvant (or neoadjuvant) chemotherapy, depending on the localisation, stage, and histopathological grading of the tumor. The poor quality of life associated with the illness and its treatment justify the application of an effective supportive therapy in order to maintain and improve the relief of symptoms and the results obtained by standard therapy. Local recurrences and distant metastases are particularly frequent with this form of cancer.
An open label clinical study was performed at the Semmelweis University's Clinic of Oral and Maxillofacial Surgery in Budapest in which 43 patients with locally advanced oral cavity squamous cell carcinoma (UICC stages II-III, and locally advanced- stage IV, i.e.T4N0M0) aged between 18 and 80 with a definitive diagnosis of less than 3 months took part. 21 of these patients received the standard anticancer therapy (SAT - consisting of radical surgery and postoperative radiation or adjuvant chemotherapy), while the remaining 22 patients received SAT and a one-year complementary treatment with Avemar. The incidence of local recurrences and disease progression differed significantly between the two groups: 4.5% and 9.09 % in the SAT+A group against 57.1% and 61.9 % in the control group (p<0.001).
A non-comparative quality of life (QOL) study involving 50 patients with head and neck cancer was also performed in the Oto-rhino-laryngology Clinic at Semmelweis University, in which 22 experienced substantial improvement in cachectic symptoms and a long-term delay of progression was observed in five out of six salivary gland tumor patients.
The above results suggest that the supportive use of Avemar in this localisation may improve QOL and enhance the anti-tumor effectiveness of standard oncotherapy (Fulop et al., 2004; Ujpal et al., 2006)
| |
SAT+Avemar
(n=22) |
SAT
(n=21) |
| Local Recurrence |
4.5 % |
57.1 % |
| Disease Progression |
9.09 % |
61.09 % |
|
TOP
